within Pharmacolibrary.Drugs.ATC.H;

model H03AA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 2e-06,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.01,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>H03AA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Thyroid gland preparations refer to desiccated animal thyroid extracts traditionally used for the treatment of hypothyroidism. These preparations contain both thyroxine (T4) and triiodothyronine (T3), and were formerly a mainstay therapy for hypothyroid patients. Today, their use is limited, having been largely replaced by synthetic levothyroxine, but some patients with hypothyroidism may still receive them.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for oral administration in adult hypothyroid patients based on known PK of main active substances (T4 and T3); no direct literature available for composite thyroid gland preparations as a whole.</p><h4>References</h4><ol><li><p>Hamdy, RC, &amp; Daley, DN (2012). Oral calcitonin. <i>International journal of women&#x27;s health</i> 4 471–479. DOI:<a href=&quot;https://doi.org/10.2147/IJWH.S24776&quot;>10.2147/IJWH.S24776</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23071417/&quot;>https://pubmed.ncbi.nlm.nih.gov/23071417</a></p></li><li><p>LeBoff, MS, et al., &amp; Larsen, PR (1982). Bioavailability of thyroid hormones from oral replacement preparations. <i>Metabolism: clinical and experimental</i> 31(9) 900–905. DOI:<a href=&quot;https://doi.org/10.1016/0026-0495(82)90179-2&quot;>10.1016/0026-0495(82)90179-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7121261/&quot;>https://pubmed.ncbi.nlm.nih.gov/7121261</a></p></li><li><p> (2005). Amended final report on the safety assessment of polyacrylamide and acrylamide residues in cosmetics. <i>International journal of toxicology</i> 24 Suppl 2 21–50. DOI:<a href=&quot;https://doi.org/10.1080/10915810590953842&quot;>10.1080/10915810590953842</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16154914/&quot;>https://pubmed.ncbi.nlm.nih.gov/16154914</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end H03AA05;
